Recap: PTC Therapeutics Q2 Earnings

Shares of PTC Therapeutics PTCT decreased in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 35.88% year over year to ($1.68), which beat the estimate of ($1.82).

Revenue of $116,676,000 rose by 55.07% year over year, which beat the estimate of $110,500,000.

Guidance

PTC Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Jul 29, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/6jhc5w2q

Technicals

52-week high: $70.82

Company's 52-week low was at $37.12

Price action over last quarter: down 6.46%

Company Description

PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!